EurekaMag.com logo
+ Site Statistics
References:
53,517,315
Abstracts:
29,339,501
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Prophylactic use of ofloxacin in granulocytopenic patients with hematological malignancies during post-remission chemotherapy



Prophylactic use of ofloxacin in granulocytopenic patients with hematological malignancies during post-remission chemotherapy



Internal Medicine 31(3): 319-324



The prophylactic efficacy of ofloxacin (OFLX) therapy was evaluated in 51 granulocytopenic episodes in 22 patients with hematological malignancies during post-remission chemotherapy in a prospective, randomized, controlled trial. Oral administration of OFLX plus amphotericin-B (AMPH) and polymyxin-B (PL) reduced episodes of fever and infection more than did the control regimen with PL and AMPH alone (p less than 0.01), and the reduction in the incidence of infection was evident even in patients showing severe granulocytopenia (p less than 0.01). Furthermore, the first fever after the onset of granulocytopenia in the OFLX regimen developed later than that in the control regimen (p less than 0.05). Clinically, the prophylactic efficacy was 92% for the OFLX regimen and 40% for the control regimen (p less than 0.01). These findings suggest that OFLX is a promising prophylactic agent following post-remission chemotherapy. Patient hemomyelogram findings similar to those of patients with other malignancies may imply that OFLX is widely effective in granulocytopenic patients taking aggressive chemotherapy.

(PDF same-day service: $19.90)

Accession: 041099923

Download citation: RISBibTeXText

PMID: 1611181

DOI: 10.2169/internalmedicine.31.319



Related references

Prophylactic effect of tropisetron hydrochloride against nausea and vomiting in patients receiving chemotherapy for hematological malignancies. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 34(9): 1513-1515, 2007

Moderately ablative chemotherapy, hematopoietic stem cell transplantation , and prophylactic donor lymphocyte infusions for poor prognosis patients with hematological malignancies. Blood 94(10 SUPPL 1 PART 1): 349a, Nov 15, 1999

A prospective randomized study of prophylactic teicoplanin to prevent early hickman catheter related sepsis in patients receiving intensive chemotherapy for hematological malignancies. Journal of Antimicrobial Chemotherapy 28(1): 109-116, 1991

Predicting early post-chemotherapy adverse events in patients with hematological malignancies: a retrospective study. Supportive Care in Cancer 24(6): 2727-2733, 2016

Double-blind randomized study of prophylactic trimethoprim/sulfamethoxazole in granulocytopenic patients with hematologic malignancies. American Journal of Medicine 74(6): 934-940, 1983

Ceftazidime and amikacin as empiric antibiotic therapy of febrile granulocytopenic patients with hematological malignancies. Report of 171 consecutive episodes. Hematological Oncology 9(3): 137-146, 1991

Chemotherapy in elderly patients with hematological malignancies. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 38(10): 1586-1590, 2011

Use of ofloxacin in prevention and treatment of secondary infections in hematological malignancies. ChemoTherapy 37 Suppl 1: 25-32, 1991

Treatment and prevention of secondary infections in hematological malignancies by ofloxacin. Japanese Archives of Internal Medicine 34(9): 315-321, 1987

Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. Plos One 8(2): E55870-E55870, 2013

Successful Remission Rates and Survival after Lymphodepleting Chemotherapy for Relapsed Hematologic Malignancies Post Allogeneic Hematopoietic Cell Transplant. 2011

Effect of post-remission chemotherapy preceding allogeneic hematopoietic cell transplant in patients with acute myeloid leukemia in first remission. Leukemia & Lymphoma 51(9): 1699-1704, 2010

Central venous catheter-related complications in patients with hematological malignancies: a retrospective analysis of risk factors and prophylactic measures. Leukemia & Lymphoma 44(9): 1495-1501, 2003

The Impact of Chemotherapy on Hepatitis B Antibody Titer in Patients with Hematological Malignancies. Turkish Journal of Haematology 32(3): 251-256, 2015

Liver function in patients with hematological malignancies and HCV infection undergoing chemotherapy. Blood 88(10 SUPPL 1 PART 1-2): 222A, 1996